The 1788 Platform is cleared to visualize CYTALUX®. CYTALUX is approved to help surgeons identify malignant and non-malignant lesions in adult patients with known or suspected lung cancer. It is an FDA approved targeted imaging agent designed to “highlight” lung cancer in the body, helping surgeons to see it in real-time as they operate.¹

CYTALUX, manufactured by On Target Laboratories, is administered intravenously 1-24 hours prior to surgery for lung cancer. The agent then circulates through the body, binding to cells and fluoresces using a specialized camera system. During a Phase 3 clinical trial², CYTALUX enabled the detection of more cancer for removal³. The 1788 Platform is now cleared to visualize CYTALUX intraoperatively.